• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

PreciseDx’s AI-Enabled Digital Pathology Proven to Detect Early-Stage Parkinson’s Disease

by Jasmine Pennic 04/20/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
PreciseDx's AI-Enabled Digital Pathology Proven to Detect Early-Stage Parkinson's Disease

What You Should Know:

– Mount Sinai spinout, PreciseDx, today announced that its AI-enabled digital pathology is the first proven to detect early-stage Parkinson’s disease, according to a recent research study.

– The study, conducted in collaboration with Michael J. Fox Foundation, identified that PreciseDx’s technology can accurately diagnose Parkinson’s disease in living patients prior to the severe onset of symptoms.


Challenges Diagnosing Parkinson’s Disease

Diagnosing Parkinson’s disease is challenging at all stages due to variable symptoms, comorbidities, and mimicking conditions, with definitive diagnosis only coming postmortem. This groundbreaking study found that PreciseDx’s AI-enabled technology is able to facilitate a conclusive diagnosis of Parkinson’s, providing critical information for earlier treatment.

PreciseDx’s AI Morphology Feature Array was able to detect Parkinson’s pathology in image patches from biopsy samples with 99% sensitivity and 99% specificity as compared to expert annotated ground truth. The AI edged out the human pathologist with an accuracy of 0.69 versus 0.64 in the prediction of clinical Parkinson’s disease status.

PreciseDx’s MFA approach to feature extraction and analysis enables new algorithms to be developed and validated against clinical endpoints. This is extremely valuable to create new diagnostic tests, accurate and reproducible diagnosis, prognosis, patient selection of therapy for a wide range of conditions.

“Traditionally, pathology grading systems look at a few morphology components to make a diagnosis. Unlike any human-powered grading method, PreciseDx’s AI Morphology Feature Array (MFA) can examine thousands of different features and leverage those relationships between them,” said John F. Crary, MD-PhD, a Professor in the Departments of Pathology, Neuroscience, and Artificial Intelligence & Human Health at the Icahn School of Medicine at Mount Sinai. “This industry-changing study has shown that we need to revitalize the way we think about pathology and lean into using AI to detect diseases more accurately, such as PD. This enlightens the industry to a direct case study into how computational pathology can truly advance medicine in terms of accurately identifying and detecting diseases.”

For more information about the study, visit https://pubmed.ncbi.nlm.nih.gov/35164870/

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, algorithms, Artificial Intelligence, case study, Digital Pathology, f, MD, Michael J. Fox Foundation, Mount Sinai, NIH, Parkinson's Disease, PhD

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |